U.S. Laboratory Informatics Market Size, Share & Forecast 2026–2032

ID: MR-11163 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Laboratory Informatics Market
  • ✓Market Size 2024: USD 1.12 billion
  • ✓Market Size 2032: USD 2.04 billion
  • ✓CAGR: 7.8%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Cloud Migration Stalls at Validation: Thermo Fisher's SampleManager and LabVantage hold the largest installed bases in U.S. regulated labs, yet cloud-native vendors like Benchling are winning greenfield biotech accounts. Validation effort under 21 CFR Part 11 is the binding constraint on migrating legacy systems.
FINDING 02
EHR Bundling Overstated: Consensus treats EHR-bundled lab modules from Epic and Oracle as the end of standalone LIS vendors. Hospital reference lab tenders increasingly procure best-of-breed informatics for molecular and genomics workflows, keeping independent vendors such as LabWare relevant.
ANALYST RECOMMENDATION

Analyst Recommendation — Pilot Cloud LIMS Now: Biotech buyers should launch a cloud LIMS pilot at a GMP site by Q4 2026, using vendor-supplied 21 CFR Part 11 validation packages. Early adoption secures multi-year pricing before the 2027 renewal cycle, when incumbent on-premise support contracts reprice.

U.S. Laboratory Informatics: Market Overview

The United States is the largest national market for laboratory informatics, supported by a dense concentration of clinical reference laboratories, hospital systems, and biopharmaceutical developers in Massachusetts, New Jersey, California, and North Carolina. Spending is shaped by regulated workflows rather than general research: CLIA-certified testing, FDA-governed drug development, and College of American Pathologists accreditation all require auditable electronic records. Compared with the global norm, American buyers adopt cloud-based systems earlier, although validation requirements still slow replacement of legacy installations.

The market was valued at USD 1.12 billion in 2024 and is forecast to reach USD 2.04 billion by 2032, a CAGR of 7.8%. Revenue is weighted toward software licenses and subscriptions, with services accounting for a substantial share because each implementation must be validated before go-live. Thermo Fisher Scientific, LabVantage Solutions, and LabWare hold strong installed bases, while newer entrants compete on usability, API depth, and faster configuration for cell and gene therapy workflows.

Growth Drivers in U.S. Laboratory Informatics

Three country-specific forces drive demand. First, FDA electronic records rules under 21 CFR Part 11 and the agency's data integrity guidance push laboratories to replace paper and spreadsheet processes. Second, the 21st Century Cures Act and ONC interoperability rules require standardized data exchange, pulling clinical laboratories toward modern interfaces. Third, federal research funding, with NIH appropriations of roughly USD 47 billion in fiscal 2024, sustains academic and nonprofit laboratory investment across the country.

Cell and gene therapy development is the fastest-growing source of new demand. The FDA has approved dozens of these products, and each sponsor must track chain-of-identity and chain-of-custody data across manufacturing and clinical sites, which spreadsheets cannot support. Demand is concentrated in Boston, the San Francisco Bay Area, and the Research Triangle, where biotech clusters are actively expanding LIMS and electronic lab notebook footprints.

Market Restraints and Entry Barriers

The most significant barrier is validation cost. Under 21 CFR Part 11 and GAMP 5 practice, each configuration change in a GxP system requires documented testing, so vendors and buyers spend heavily on qualification. Legacy LIS installations in hospitals also run on HL7 v2 interfaces that are costly to migrate, and integration with Epic and Oracle Health electronic health records adds further project time and cost.

Incumbent advantage and procurement structure compound the problem. Large vendors such as Thermo Fisher Scientific and LabWare hold multi-year enterprise agreements, while hospital group purchasing organizations bundle clinical informatics into broader EHR contracts. New York's Clinical Laboratory Evaluation Program requires separate approval for laboratories serving New York patients, lengthening the timeline for any new system deployment and state-level compliance review.

Market Opportunities in U.S. Laboratory Informatics

The most accessible near-term opportunity lies with clinical-stage biotechnology companies in Boston, San Diego, and the San Francisco Bay Area that are moving from spreadsheets to validated electronic systems ahead of Phase 3 readiness. An analyst estimate places addressable cloud LIMS and electronic lab notebook spend in this cohort at roughly USD 310 million in 2025, growing faster than the wider market. Vendors offering pre-validated templates for cell and gene therapy workflows can shorten sales cycles considerably.

Hospital outreach and public health laboratories represent a second opening. State and local public health laboratories rely on federal grants administered through the CDC, and modernization funding has prioritized data interoperability with state surveillance systems. Independent reference laboratories processing high volumes of molecular tests also need automated sample tracking, creating demand for configurable middleware that connects analyzers to EHR interfaces without full system replacement.

Market at a Glance

IndicatorValue
Market Size 2024USD 1.12 billion
Market Size 2032USD 2.04 billion
Growth Rate (CAGR)7.8%
Most Critical Decision FactorValidation effort and vendor Part 11 compliance readiness
Largest RegionNortheast (Massachusetts and New Jersey corridors)
Competitive StructureConcentrated top tier with fragmented mid-market

Leading Market Participants

  • Thermo Fisher Scientific
  • LabVantage Solutions
  • LabWare
  • Agilent Technologies
  • Waters Corporation
  • Benchling
  • Dassault Systèmes
  • Revvity
  • Sapio Sciences
  • Oracle Health

Regulatory and Policy Environment

Clinical laboratories operate under the Clinical Laboratory Improvement Amendments, administered by the Centers for Medicare and Medicaid Services under 42 CFR Part 493, and accredited through the College of American Pathologists. Drug developers must comply with FDA 21 CFR Part 11 on electronic records and signatures, while the FDA's data integrity guidance governs audit trail expectations. The ONC Health Data, Technology, and Interoperability rule and the 21st Century Cures Act information blocking provisions shape how laboratory systems exchange data with certified EHRs.

Compliance timelines are set by these frameworks. CLIA certificates require renewal every two years, and laboratories must maintain proficiency testing throughout. HIPAA Security Rule obligations apply to any cloud-hosted laboratory data, requiring business associate agreements with informatics vendors. Federal research funding through the National Institutes of Health and CDC public health laboratory grants provides indirect subsidy support, while Medicare Clinical Laboratory Fee Schedule reimbursement shapes hospital laboratory budgets for informatics investment.

Long-Term Outlook for U.S. Laboratory Informatics

By 2032, cloud-based deployments will represent the majority of new U.S. laboratory informatics contracts, as validated SaaS packages reduce the qualification burden that has historically favored on-premise systems. Revenue growth of 7.8% per year will be led by biopharmaceutical and cell and gene therapy customers, while hospital laboratories modernize more slowly because of EHR consolidation and integration complexity.

Competitive structure will consolidate around vendors offering AI-assisted data review, instrument connectivity, and audit-ready configuration. Diversified life-science tools companies will acquire mid-sized independent LIMS providers, while Thermo Fisher Scientific, Agilent Technologies, and Waters Corporation strengthen their positions through platform bundling. Market value is projected to reach USD 2.04 billion by 2032.

Frequently Asked Questions

Most successful entrants partner with an established reseller or systems integrator that already holds validation expertise. Direct entry works best in biotech segments where cloud-validated packages reduce deployment time.
Validation typically takes several months for a single GxP site, depending on configuration complexity. Vendors offering pre-built validation packages can cut this timeline materially.
Yes, laboratories testing New York patients must hold New York State approval through the Clinical Laboratory Evaluation Program. Vendors should plan separate compliance review for any New York client.
Clinical-stage biotechnology companies typically move fastest because they are replacing spreadsheets rather than legacy systems. Hospital laboratories usually require longer procurement cycles through group purchasing organizations.
Subscription pricing based on user count and instrument connections is replacing perpetual licenses. Vendors increasingly bundle validation and support into annual contracts.

Market Segmentation

By Deployment Mode
  • Cloud-Based (SaaS)
  • On-Premise
  • Hybrid
  • Managed Hosting
  • Others
By End User
  • Hospital and Health System Labs
  • Pharmaceutical and Biotechnology
  • Contract Research Organizations
  • Public Health and Reference Labs
  • Others
By Component
  • Software Licenses
  • Implementation Services
  • Validation and Compliance Services
  • Support and Maintenance
  • Others

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Laboratory Informatics - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Deployment Mode Insights
4.1 Cloud-Based (SaaS)
4.2 On-Premise
4.3 Hybrid
4.4 Managed Hosting
4.5 Others
Chapter 05 End User Insights
5.1 Hospital and Health System Labs
5.2 Pharmaceutical and Biotechnology
5.3 Contract Research Organizations
5.4 Public Health and Reference Labs
5.5 Others
Chapter 06 Component Insights
6.1 Software Licenses
6.2 Implementation Services
6.3 Validation and Compliance Services
6.4 Support and Maintenance
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Thermo Fisher Scientific
7.2.2 LabVantage Solutions
7.2.3 LabWare
7.2.4 Agilent Technologies
7.2.5 Waters Corporation
7.2.6 Benchling
7.2.7 Dassault Systèmes
7.2.8 Revvity
7.2.9 Sapio Sciences
7.2.10 Oracle Health
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.